Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16283377 | 0.85 | KDM4E (0.38) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL16410985 | 0.81 | — | — | |
| SCHEMBL16285287 | 0.79 | MMP3 (0.33) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL13034679 | 0.76 | KDM4E (0.38) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL18216685 | 0.76 | PTGS1 (0.36) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL20706151 | 0.73 | KDM4E (0.36) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL13233684 | 0.73 | — | — | |
| SCHEMBL13227961 | 0.73 | — | — | |
| SCHEMBL2614011 | 0.73 | — | — | |
| SCHEMBL16451650 | 0.70 | KDM4E (0.36) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303247-A1 | Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods | IGENICA BIOTHERAPEUTICS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20130224228-A1 | Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods | IGENICA, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013085925-A1 | ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS | IGENICA, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303247-A1 | Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods | SDCBP, CD81, NGLY1 | KDM4E 1917/4885MAPT 1050/4885THRB 2403/4885 |
| US-20130224228-A1 | Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods | SDCBP, CD81, NGLY1 | KDM4E 1917/4885MAPT 1050/4885THRB 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.